GNTA
Genenta ScienceGNTA
GNTA
About: Genenta Science SPA is a clinical-stage biotechnology company engaged in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors and cancer. The company's products include Temferon - a product to treat glioblastoma multiforme, a solid tumor affecting the brain.
Employees: 13
0
Funds holding %
of 7,457 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
100% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 1
48% more capital invested
Capital invested by funds: $1.42M [Q4 2024] → $2.1M (+$680K) [Q1 2025]
25% more funds holding
Funds holding: 4 [Q4 2024] → 5 (+1) [Q1 2025]
0.97% more ownership
Funds ownership: 1.97% [Q4 2024] → 2.95% (+0.97%) [Q1 2025]
Research analyst outlook
We haven’t received any recent analyst ratings for GNTA.
Financial journalist opinion
Neutral
Newsfile Corp
1 week ago
Genenta Science, SpA Announces Participation in the D. Boral Capital Inaugural Global Conference
Milan, Italy and New York, New York--(Newsfile Corp. - May 8, 2025) - Genenta Science, SpA (NASDAQ: GNTA), today announced its participation in the D. Boral Capital Inaugural Global Conference, taking place May 14, 2025, at The Plaza Hotel in New York City.
Neutral
GlobeNewsWire
1 week ago
Genenta and Anemocyte announce a collaboration for the manufacturing of starting materials for cutting-edge cell-based therapies
MILAN and NEW YORK, May 07, 2025 (GLOBE NEWSWIRE) -- Genenta Science (Nasdaq: GNTA), a pioneer in immuno-oncology and a leader in cell-based therapeutics, today announced a collaboration with Anemocyte, a leading Biotech Manufacturing Organization (BMO) based in Italy. This strategic partnership marks a major milestone, encompassing the successful production of critical starting materials, including the establishment of Cell Banks and the manufacturing of Plasmids for viral vector production.
Neutral
GlobeNewsWire
1 month ago
Genenta Showcases Strategic Vision at Premier Biotech Forum in Qatar
MILAN and NEW YORK, April 15, 2025 (GLOBE NEWSWIRE) -- Pierluigi Paracchi, CEO Genenta Science (Nasdaq: GNTA), a pioneer in immuno-oncology and a leader in cell-based therapeutics, will present at “Montalcini Global Biotech Tour” in Doha, Qatar on April 17th, 2025 at the Sheikh Fahad bin Jassim Al Thani theatre, Ministry of Commerce and Industry (MOCI) Building. Following the announcement of a €20 million ($22.7 million) strategic financing through the issuance of a Mandatory Convertible Bond to ENEA Tech and Biomedical (ETB) — aimed at expanding Genenta's pipeline with the advancement of Temferon™ in metastatic Renal Cell Cancer (mRCC) — and the addition of approximately €3.0 million ($3.2 million) raised via at-the-market (ATM) facility, Genenta CEO Pierluigi Paracchi will present at the event, which will be hosted by H.E.
Neutral
GlobeNewsWire
1 month ago
Genenta Announces €20 million ($21.9M) Financing To Expand Pipeline As Brain Tumor Trial Is Showing Promising Survival Rates
MILAN and NEW YORK, March 19, 2025 (GLOBE NEWSWIRE) -- Genenta Science (Nasdaq: GNTA), a pioneer in immuno-oncology and a leader in cell-based therapeutics, today announced a €20 million ($21.9 million) financing through the issuance of a Mandatory Convertible Bond to ENEA Tech and Biomedical (ETB) to support the expansion of its pipeline by advancing Temferon in metastatic Renal Cell Cancer (mRCC). ETB is a leading private foundation, supervised by the Italian Ministry of Enterprises and Made in Italy, managing over €1,7 billion in assets under management through two funds.
Neutral
PRNewsWire
3 months ago
TOP ITALIAN AND U.S. LIFE SCIENCES EXECUTIVES AND ITALIAN GOVERNMENT LEADERS SHARED BUSINESS SUCCESS STORIES WITH INVESTORS AT "ITALY ON THE MOVE 2025" SIDE EVENT DURING J.P. MORGAN HEALTHCARE CONFERENCE
Over 230 Italian and U.S. executives, Italian government leaders, and investors attended the eighth edition of "Italy On the Move" Seven life sciences executives provided business insights during "Navigating Transatlantic Partnerships in Life Sciences" panel discussion and five Italian startups pitched their unique breakthroughs and investment opportunities Director General for the Promotion of Italy Mauro Battocchi discussed private and public/institutional financial opportunities in the €270 Billion Italian life sciences sector 1 SAN FRANCISCO , Jan. 28, 2025 /PRNewswire/ -- The Italian Trade Agency (ITA) collaborated with the Ministry of Foreign Affairs and International Cooperation to host the eighth edition of "Italy on the Move," a side event during the 43rd annual J.P. Morgan Healthcare Conference 2025 at INNOVIT - The Italian Innovation and Culture Hub.
Neutral
GlobeNewsWire
4 months ago
Genenta Strengthens Agreement with AGC Biologics to Boost Cell Therapy Manufacturing
MILAN and NEW YORK, Jan. 09, 2025 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ: GNTA), a pioneer in immuno-oncology and a leader in cell-based therapeutics, is pleased to announce that it has strengthened its partnership with AGC Biologics, a global contract development and manufacturing organization (CDMO), by amending their Development and Master Services Agreement. This amendment introduces an exclusive GMP suite at the AGC Biologics Cell and Gene Center of Excellence in Milan, dedicated to the manufacturing of Genenta's cell therapy product, ensuring compliance with cGMP standards.
Neutral
PRNewsWire
4 months ago
ITALIAN TRADE AGENCY TO HOST "ITALY ON THE MOVE 2025" SIDE EVENT DURING J.P. MORGAN HEALTHCARE CONFERENCE
Event showcases Italy as leading competitive hub for investments in biotech, healthcare, medical devices, and pharmaceuticals, and includes experts discussing private and public/institutional financial opportunities in the €270 Billion Italian life sciences sector 1 SAN FRANCISCO , Jan. 8, 2025 /PRNewswire/ -- To promote investment opportunities in Italy in 2025, the Italian Trade Agency (ITA) and the Ministry of Foreign Affairs and International Cooperation will be hosting the eighth edition of "Italy on the Move," a side event of the 43rd annual J.P. Morgan Healthcare Conference 2025.
Neutral
GlobeNewsWire
6 months ago
Genenta's CEO to present at the U.S. Senate meeting on “Cross-Border Investments and Strategies in the Biotechnology Sector: A Transatlantic Perspective”
Genenta's CEO to present at the U.S. Senate, Washington D.C.at the meeting “Cross-Border Investments and Strategies in the Biotechnology Sector: A Transatl
Neutral
GlobeNewsWire
7 months ago
Genenta Secures Approval for Innovative Trial for Metastatic Renal Cell Cancer
MILAN and NEW YORK, Oct. 02, 2024 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ: GNTA), a pioneer in immuno-oncology and a leader in cell-based therapeutics, is pleased to announce that the Agenzia Italiana del Farmaco (AIFA) has approved a new Phase 1 clinical trial for metastatic Renal Cell Cancer (mRCC), marking a significant expansion of the potential applications for Genenta's flagship product, Temferon™. This approval by AIFA is in line with the standards that are harmonized across European regulatory frameworks established by the European Medicines Agency (EMA).
Neutral
InvestorPlace
11 months ago
7 Penny Biotech Stocks to Triple Your Investment
One of the oldest maxims in investing is that higher risk produces greater returns. That maxim holds particularly true across penny biotech stocks.
Charts implemented using Lightweight Charts™